Exome data clouds the pathogenicity of genetic variants in Pulmonary Arterial Hypertension by Abbasi, Yeganeh et al.
u n i ve r s i t y  o f  co pe n h ag e n  
Københavns Universitet
Exome data clouds the pathogenicity of genetic variants in Pulmonary Arterial
Hypertension
Abbasi, Yeganeh; Jabbari, Javad; Jabbari, Reza; Glinge, Charlotte; Izadyar, Seyed Bahador;
Spiekerkoetter, Edda; Zamanian, Roham T.; Carlsen, Jørn; Tfelt-Hansen, Jacob
Published in:
Molecular Genetics and Genomic Medicine
DOI:
10.1002/mgg3.452
Publication date:
2018
Document version
Publisher's PDF, also known as Version of record
Document license:
CC BY
Citation for published version (APA):
Abbasi, Y., Jabbari, J., Jabbari, R., Glinge, C., Izadyar, SB., Spiekerkoetter, E., ... Tfelt-Hansen, J. (2018).
Exome data clouds the pathogenicity of genetic variants in Pulmonary Arterial Hypertension. Molecular Genetics
and Genomic Medicine, 6(5), 835-844. https://doi.org/10.1002/mgg3.452
Download date: 03. Feb. 2020
OR I G I N A L AR T I C L E
Exome data clouds the pathogenicity of genetic variants in
Pulmonary Arterial Hypertension
Yeganeh Abbasi1,2 | Javad Jabbari3 | Reza Jabbari1,2 | Charlotte Glinge1 |
Seyed Bahador Izadyar1 | Edda Spiekerkoetter4 | Roham T. Zamanian4 | Jørn Carlsen1,2 |
Jacob Tfelt-Hansen1,2,5
1Heart Centre, Department of Cardiology,
Copenhagen University Hospital,
Rigshospitalet, Copenhagen, Denmark
2Department of Cardiology, Section for
Pulmonary Hypertension and Right Heart
Failure, Copenhagen University Hospital,
Rigshospitalet, Copenhagen, Denmark
3LEO Pharma A/S, Ballerup, Denmark
4Division of Pulmonary and Critical
Care, Stanford University School of
Medicine, California
5Department of Forensic Medicine,
Faculty of Medical Sciences, University
of Copenhagen, Denmark
Correspondence
Yeganeh Abbasi, The Heart Centre,
Copenhagen University Hospital,
Rigshospitalet, Blegdamsvej 9, 2100
Copenhagen Ø, Denmark.
Email: yeganehabasi@gmail.com
Funding information
Novo Nordisk
Abstract
Background: We aimed to provide a set of previously reported PAH‐associated
missense and nonsense variants, and evaluate the pathogenicity of those variants.
Methods: The Human Gene Mutation Database, PubMed, and Google Scholar
were searched for previously reported PAH‐associated genes and variants.
Thereafter, both exome sequencing project and exome aggregation consortium
as background population searched for previously reported PAH‐associated
missense and nonsense variants. The pathogenicity of previously reported
PAH‐associated missense variants evaluated by using four in silico prediction
tools.
Results: In total, 14 PAH‐associated genes and 180 missense and nonsense vari-
ants were gathered. The BMPR2, the most frequent reported gene, encompasses
135 of 180 missense and nonsense variants. The exome sequencing project com-
prised 9, and the exome aggregation consortium counted 25 of 180 PAH‐asso-
ciated missense and nonsense variants. The TOPBP1 and ENG genes are unlikely
to be the monogenic cause of PAH pathogenesis based on allele frequency in
background population and prediction analysis.
Conclusion: This is the first evaluation of previously reported PAH‐associated
missense and nonsense variants. The BMPR2 identified as the major gene out of
14 PAH‐associated genes. Based on findings, the ENG and TOPBP1 gene are not
likely to be the monogenic cause of PAH.
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1 | INTRODUCTION
Pulmonary arterial hypertension (PAH) is a rare, progres-
sive, and deathly disease (Hoeper et al., 2014; Machado,
2012; Simonneau et al., 2013). Despite advances in treat-
ment of the PAH, the mortality rate is still high (Ling et
al., 2012). The incidence of PAH estimated in a wide range
from 2.4 to 25 cases per million per year (Gaine & Rubin,
1998; Humbert et al., 2006; Ling et al., 2012).
PAH is subclassified into four groups: idiopathic PAH,
heritable PAH, drug, and toxin induced, and lastly associ-
ated with certain other diseases (e.g. connective tissue
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disease, HIV infection, portal hypertension, congenital
heart diseases, and schistosomiasis) (Simonneau et al.,
2013).
The pathogenesis of PAH is complex, and, albeit the
extensive effort, is still not completely understood (Badesch
et al., 2009; Hoeper et al., 2013; Simonneau et al., 2013)
Genetic studies have identified association of several
genetic loci to PAH (Austin & Loyd, 2014; Rabinovitch,
2012; Simonneau et al., 2013). The bone morphogenetic
protein receptor type II (BMPR2) plays a major role in the
etiology of idiopathic and heritable PAH (Ma & Chung,
2014; Simonneau et al., 2013). Other reported PAH‐asso-
ciated genes includes activin A receptor like type 1
(ACVRL1), endoglin (ENG), SMAD family 1,4, 9, caveolin
1 (CAV1), bone morphogenetic protein receptor type 1b
(BMPR1B), potassium voltage‐gated channel subfamily a
member 5 (KCNA5), potassium channel subfamily K mem-
ber 3 (KCNK3), T‐box transcription factor 4 (TBX4), DNA
topoisomerase 2‐binding protein 1 (TOPBP1), growth dif-
ferentiation factor 2 (GDF2) and eukaryotic translation ini-
tiation factor 2‐alpha kinase 4 (EIF2AK4) at a lower
frequency (Machado, 2012; Soubrier et al., 2013). The
genes that were classified as PAH‐associated genes in the
guideline were BMPR2, ALK-1, ENG, SMAD9, CAV1, and
KCNK3 (Simonneau et al., 2013). Genetic testing has
become an important tool in the clinical evaluation of PAH
patients, especially for patients with a positive family his-
tory of PAH. Therefore, it is important to determine
whether PAH associated genes and variants are truly dis-
ease causing.
We aimed to provide an encyclopedia by gathering all
previously published PAH‐associated genes and variants,
and further evaluate the pathogenicity of each variant by
performing comprehensive in silico prediction analysis,
together with investigating the frequency of each PAH‐
associated variant in two large online exome databases.
2 | MATERIALS AND METHODS
The Human Gene Mutation Database (HGMD), PubMed,
and Google Scholar were searched for previously published
PAH‐associated genes and variants until October 2016. The
following queries were used: ((ʻpulmonary arterial hyper-
tension ʼ (MeSH)) or (pulmonary arterial hypertension)),
((ʻgeneticsʼ (MeSH)) or (genetic)), ((ʻmutationʼ (MeSH)) or
(mutation)) and ((ʻvariantsʼ (MeSH)) or (variants)). We
revisited all identified genetic variants searching for pub-
lished data on functional and familial cosegregation studies.
In order to have a solid baseline, familial cosegregation
was defined as at least two genotype positive family mem-
bers having the same phenotype. The Hugo Genome
Organisation and Gene Nomenclature Committee was used
for standard nomenclature of human genes (HGNC data-
base of human gene names | HUGO Gene Nomenclature
Committee). The publicly available Ensembl genome data-
base was used to find the location of variants in the gen-
ome and determine the amino acid changes in the protein
coding regions of genes (Ensembl Genome Browser 85).
2.1 | Exome sequencing project
In the Exome Sequencing Project (ESP), next‐generation
sequencing of all protein coding regions in 6,503 individu-
als of African American (n = 2,203) and European Ameri-
can (n = 4,300) from different population studies have
been carried out (Exome Variant Server). Clinical data
were not available. The ESP was searched for previously
published PAH‐associated variants. The ESP lacks the data
regarding variants positioned in promotors, introns, and
untranslated regions, therefore variants found in these
regions were not included in present study.
All previously identified PAH‐associated variants in our
investigation were subdivided into two groups; those that
were identified in the ESP (ESP‐ positive) and those that
were not identified in the ESP (ESP‐negative).
2.2 | The exome aggregation consortium
In the exome aggregation consortium (ExAC) comprehend
exome sequencing data from 60,706 unrelated individuals
(ExAC Browser). African/African American (n = 5,203),
Latino (n = 5,789), East Asian (n = 4,327), Finnish
(n = 3,307), Non‐Finnish European (n = 33,370), South
Asian (n = 8,256), and other (n = 454) nationalities are
presented in the ExAC database (ExAC Browser). Like the
ESP, this browser only encompasses human genome data
that encodes proteins as part of several various exome‐stu-
dies on populations with specific diseases (ExAC Browser).
The PAH‐associated variants were subdivided into those that
were identified in the ExAC (ExAC‐positive) and those that
were not identified in the ExAC (ExAC‐negative).
The ESP and ExAC databases are considered as back
ground population in this study.
2.3 | In silico prediction analysis
The functional effects of all missense variants were
assessed by using the four prediction tools including con-
servation across species, Grantham Score, PolyPhen‐2
(Polymorphism Phenotyping v2), and SIFT (Sorting Intol-
erant from Tolerant, v5.1.1). Data for conservation across
species were obtained from Ensembl, and classified as
occurring at a position with no substitutions (conserved/
pathogenic) or ≥1 substitutions (not conserved/benign).
Grantham physicochemical values were calculated using
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the Grantham amino acid difference matrix. We defined a
value above 100 as radical (pathogenic), and value under
100 as conservative (benign). Using PolyPhen‐2, each vari-
ant were labeled “probably damaging”, “possibly damag-
ing”, or “benign”. Variants labeled “probably damaging”
and “possibly damaging” considered “damaging” (patho-
genic) in our analysis. Finally, SIFT prediction classified
variants as “tolerant” (benign) or “damaging” (pathologic).
In a final analysis using all prediction tools, a variant was
considered pathogenic if ≥3 in silico prediction tools deter-
mined the variant to be pathogenic, as previously described
(Giudicessi et al., 2012). Variants that predicted pathogenic
by only 1 or 2 tools was considered to be variants of
uncertain significance (VUS).
3 | RESULTS
To date, 14 genes and 180 missense/nonsense variants have
been identified as PAH‐associated genes and variants
(Table 1).
The BMPR2 was the most frequent reported gene and
encompasses 135 (missense=86 and nonsense=49) of the
180 identified missense/nonsense PAH‐associated variants
(Figure). The other previously identified PAH‐associated
genes: ACVRL1, BMPR1B, CAV1, KCNA5, KCNK3,
SMAD1, SMAD4, SMAD9, TBX4, TOPBP1, ENG, GDF2,
and EIF2AK4 included 45 (missense=40 and nonsense=5)
of the 180 missense/nonsense PAH‐associated variants
(Table 1).
We performed a prediction analysis of only the mis-
sense PAH‐associated variants (n = 126), because the non-
sense variants are classified to be damaging by nature of
the uncompleted translation. By doing so, 76 of 126 mis-
sense PAH‐associated variants were predicted as patho-
genic (Table 2). Accordingly, 52 of 86 PAH‐associated
missense variants in BMPR2 gene were predicted patho-
genic. Prediction analyses for all PAH‐associated genes are
available in the Table 2.
By investigating the frequency of the PAH‐associated
variants in the two large population databases, we found
that the ESP comprised 9 of 180 variants (Table 3), while
the ExAC in counted 25 PAH‐associated missens/nonsense
variants (Tables 3 and 4).
In the most frequent reported PAH‐associated gene,
BMPR2, we found 2 ESP‐positive and 12 ExAC‐positive
variants of 135 variants (Tables 3 and 4).
In the literature, functional studies had been performed
in 29 of 180 PAH‐associated variants (Table 5), assessing
the functional properties of the resulted protein using
in vivo and/or in vitro studies. All functional studies
showed that mutated proteins, except 2 variants (p.Ser160-
Asn (rs149589961) and p.Phe392Leu) in BMPR1B, dis-
played a loss of function phenotype (Table 5).
4 | DISCUSSION
In this novel study, we provide the clinicians the first com-
prehensive evaluation tool for genetic diagnostic of PAH,
by evaluating the allele frequency of previously reported
PAH‐associated variants in the two large background
TABLE 1 Overview of PAH‐associated genes and variants
Gene Missense variants Nonsense variants
BMPR2 86 49
ACVRL1 16 1
BMPR1B 2 –
CAV1 1 –
KCNA5 4 –
KCNK3 6 –
SMAD1 1 –
SMAD4 1 –
SMAD9 1 2
TBX4 3 –
TOPBP1 3 –
ENG 2 –
GDF2 – 1
EIF2AK4 – 1
14 genes 126 missense 54 nonsense
TABLE 2 Prediction analysis of missense variants with ≥ 3 in
silico prediction tools agreement
Gene Damaging VUS Benign
BMPR2 52 24 10
ACVRL1 (ALK1) 13 2 1
BMPR1B (ALK6) 0 2 0
CAV1 0 0 1
KCNA5 2 2 0
KCNK3 5 1 0
SMAD1 0 1 0
SMAD4 0 1 0
SMAD9 1 0 0
TBX4 2 0 1
TOPBP1 1 1 1
ENG 0 2 0
76 36 14
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population databases (ESP and ExAC), and also by adding
in silico prediction analysis using an established conserva-
tive method (Abbasi et al., 2016; Jabbari et al., 2013; Ris-
gaard et al., 2013). Surprisingly, in the literature we
identified very limited data on familial cosegregation, thus,
unfortunately, the familial cosegregation in our evaluation
was very limited. This, however, goes hand in hand and
support our findings that the identified ESP‐ and ExAC‐
positive variants may not be the monogenic cause of the
PAH. The pathogenic PAH‐associated variants in BMPR2
gene have reduced penetrance and gender dependant (Aus-
tin, Loyd, & Phillips, 1993). Therefore, ESP and ExAC
databases most likely include unaffected heterozygotes
parents. The penetrance information for pathogenic PAH‐
associated variants in ACVRL1, KCNK3, CAV1, SMAD9,
and BMPR1B genes is unknown (Austin et al., 1993).
Our investigation supports that the BMPR2 gene is of
major importance in the development of the heritable and
idiopathic PAH (Simonneau et al., 2013; Soubrier et al.,
2013). According to our findings, BMPR2 included 75%
(135 of 180) of the previously reported missense/nonsense
PAH‐associated variants. Familial cosegregation was only
identified for three variants (p.W13*, p.E386V and
p.K512T) in BMPR2 gene (Fu et al., 2008; Hamid et al.,
2010; Machado et al., 2006). Prediction analysis of BMPR2
missense variants (n = 86), using agreement of ≥ 3 of 4 in
TABLE 4 Exome aggregation consortium‐positive varian
Gene Variant rs ID
Allele
frequency
Grantham
score PolyPhen SIFT Conservation
Agreement
≥3 tools References
BMPR2 p.Q92H rs140683387 0.000107 24 Benign Tolerated Not conserved B Kabata et al. (2013)
p.W508* X 0.000008 – – – – – Pfarr et al. (20110
p.R591* X 0.000016 – – – – – Sztrymf et al. (2008)
p.T766A X 0.000008 58 Benign Tolerated Not conserved B Liu et al. (2012)
p.R873Q rs201781338 0.000115 43 Damaging Tolerated Conserved VUS Sztrymf et al. (2008)
p.R266T rs374694591 0.000041 71 Damaging Not
tolerated
Conserved D Machado et al. (2006)
p.R303H rs200948870 0.000033 29 Damaging Tolerated Conserved VUS Machado et al. (2006)
p.V563M X 0.000008 21 Damaging Tolerated Conserved VUS Machado et al. (2006)
p.R899P rs137852752 0.000008 103 Damaging Tolerated Not conserved VUS Vattulainen et al.
(2015)
p.A24E X 0.000008 107 Benign Tolerated Not conserved VUS Machado et al. (2009)
p.N903S rs373725296 0.000016 46 Damaging Tolerated Conserved VUS Thomas et al. (2009)
p.E427D X 0.000008 45 Benign Tolerated Conserved VUS van der Bruggen
et al. (2016)
CAV1 p.V155I rs150368249 0.000585 29 Benign Tolerated Not conserved B Austin et al., 2012;
KCNA5 p.E211D rs35853292 0.000833 45 Benign Tolerated Conserved VUS Remillard
et al. (2007)p.G182R X 0.000141 125 Damaging Not
tolerated
Conserved D
SMAD4 p.N13S rs281875323 0.000024 46 Damaging Tolerated Not conserved VUS Nasim et al. (2011)
SMAD9 p.K43E X 0.000107 56 Damaging Not
tolerated
Conserved D Nasim et al. (2011)
p.R294* X 0.000008 – – – – – Drake et al. (2011)
TBX4 p.A35V rs148424252 0.007833 64 Benign Tolerated Not conserved B Kerstjens‐Frederikse
et al., 2013; (p4)p.Y382S X 0.000041 144 Damaging Not
tolerated
Conserved D
TOPBP1 p.S817L rs17301766 0.1411 145 Benign Tolerated Not conserved VUS de Jesus Perez
et al. (2014)p.R309C rs55633281 0.0533 180 Damaging Tolerated Conserved D
p.N1042S rs10935070 0.2898 46 Benign Tolerated Not conserved B
ENG p.G214S rs150932144 0.000155 56 Damaging Tolerated Not conserved VUS Pfarr et al. (2013)
p.G545S rs142896669 0.000520 56 Damaging Tolerated Conserved VUS
Note. B: benign; D: damaging; VUS: variants with uncertain significance.
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silico prediction tools indicated that only 60.4% variants
(n = 52) were predicted pathogenic.
The annual incidence of PAH is estimated from 2.4 to
25 cases per million per year in the general population
(Gaine & Rubin, 1998; Humbert et al., 2006; Ling et al.,
2012). In total, 12 variants in BMPR2 were identified in
the ESP and ExAC databases (Tables 3 and 4). This means
~9% of previously identified PAH‐associated variants in
BMPR2 were found in the background population. Accord-
ing to the incidence of PAH in background population, this
is an expected frequency of PAH‐associated variants in
BMPR2 in the background population. The 12 identified
functional studies on variants in BMPR2 gene revealed that
all mutated proteins had a loss of function phenotype
(Table 5).Taken together, these findings point to a pivotal
role of BMPR2 in pathogenesis of PAH.
In contrast, we found all the three PAH‐associated mis-
sense variants (p.S817L [rs17301766], p.N1042S
[rs10935070] and p.R309C [rs55633281]) in TOPBP1 gene
in the ESP and ExAC databases (de Jesus Perez et al.,
2014). The allele frequency of p.S817L (in ESP = 0.1839
and in ExAC = 0.1411), p.N1042S (in ESP = 0.3239 and
in ExAC = 0.2898), and p.R309C (in ESP = 0.0708 and
in ExAC = 0.0533) in ESP and ExAC is very high
TABLE 5 Functional studies
Gene
Amino acid
substitution Type of cell/Animal Result References
ACVRL1 (ALK1) R484W NIH‐3T3 fibroblasts and COS‐7 cells Loss of function Ricard et al. (2010)
R484Q NIH‐3T3 fibroblasts and COS‐7 cells Loss of function
L381P NIH‐3T3 fibroblasts and COS‐7 cells Loss of Function
BMPR1B (ALK6) S160N COS1 cells (in vitro) Gain of function Chida et al. (2012)
F392L COS1 Cells (in vitro) Gain of function
BMPR2 W16* PASMCs and microvascular endothelial cells Loss of Function Dewachter et al. (2009)
R491W PASMCs and microvascular endothelial cells Loss of Function
Q495* PASMCs and microvascular endothelial cells Loss of Function
S301P PASMCs and microvascular endothelial cells Loss of Function
E195* PASMCs and microvascular endothelial cells Loss of Function
S107* PASMCs and microvascular endothelial cells Loss of Function
R321* Blood outgrowth endothelial cells (BOECs)
Pulmonary artery endothelial (PAEC) & Pulmonary
artery smooth muscle cells (PASMC)
Loss of Function Drake et al. (2011),
Dunmore et al. (2013)
W9* PASMCs Loss of Function Thomas et al. (2009)
C347R PASMCs Loss of Function
C347Y PASMCs Loss of Function
N903S PASMCs Loss of Function
R899* A mouse model (In vivo) Loss of Function Long et al. (2015)
KCNA5 E211D COS‐1(mammalian) cells & HEK‐293*(human) cells Loss of Function Burg et al. (2010)
G182R COS‐1(mammalian) cells & HEK‐293*(human) cells Loss of Function
KCNK3 T8K COS‐7cells Loss of Function Ma et al. (2013)
G97R COS‐7cells Loss of Function
E182K COS‐7cells Loss of Function
Y192C COS‐7cells Loss of Function
G203D COS‐7cells Loss of Function
V221L COS‐7cells Loss of Function
SMAD1 V3A PASMCs Loss of Function Nasim et al. (2011)
SMAD4 N13S PASMCs Loss of Function Nasim et al. (2011)
SMAD9 K43E PASMCs Loss of Function Nasim et al. (2011),
Suo et al. (2013)
C202* COS1 Cells Loss of Function Shintani et al. (2009)
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(Tables 3 and 4; de Jesus Perez et al., 2014). Our predic-
tion analysis showed that only p.R309C was predicted
pathogenic. Since the PAH‐associated variants in the
TOPBP1 have high allele frequency in the background
population (n = 3 variants) is not likely to be the mono-
genic cause of PAH. No functional studies have been
reported on these variants and these are indeed needed to
clarify the effect of variants in TOPBP1 as a modifier gene
in the pathogenesis of PAH. Furthermore, no familial
cosegregation are reported in order to support TOPBP1
monogenic cause of PAH (de Jesus Perez et al., 2014).
In 2013, the 5th World Symposium on Pulmonary Hyper-
tension established the ENG gene to be a PAH‐associated
gene, since two missense PAH‐associated variants (p.G214S
[rs150932144] and p.G545S [rs142896669]) were reported
(Simonneau et al., 2013). In our analysis, these two variants
were predicted VUS (Table 2), questioning the pathogenicity
of these variants in the PAH‐etiology. Furthermore, both the
p.G214S and p.G545S were present in the ESP and ExAC
databases (Tables 3 and 4). The allele frequency of p.G214S
in the ESP was 0.0002 and 0.0001 in the ExAC database.
The p.G545S variant found in the ESP with allele frequency
0.0006 and 0.0005 in the ExAC browser (Tables 3 and 4).
Although ENG gene known as a PAH‐associated gene in the
development of PAH, our data and analysis do not support
that ENG variants are likely to be a monogenic or one of the
major causes in the pathogenesis of PAH. It is important to
perform a comprehensive functional study to determine the
exact effect of the reported amino acid changes in the ENG
and the effect of p.G214S and p.G545S in expression level
of the protein.
In the literature we found five PAH‐associated variants in
SMAD genes: SMAD1 (p.V3A), SMAD4 (p.N13S) and
SMAD9 (p.K43E, p.C202* and p.R294*). None of the five
were found in the ESP, but we found three variants (p.N13S,
p.K43E and p.R294*) in the ExAC (Table 4). Using pul-
monary artery smooth muscle cells (PASMCs), Nasim M.T.
et al. demonstrated that the p.V3A in SMAD1 gene, p.N13S
in SMAD4 gene, and p.K43E in SMAD9 gene resulted in
reduced signaling activity in vitro of amino acid substitutions
(Nasim et al., 2011). Another functional study analyzed the
function of p.C202* in SMAD9 (aliases: SMAD8) by using
COS1 cells (a fibroblast‐like cell). This study revealed that
the mutated protein was not able to have interaction with
SMAD4 gene (Tables 2 and 5; Shintani, Yagi, Nakayama,
Saji, & Matsuoka, 2009). Although the p.V3A and p.N13S
were predicted as VUS, the results of functional studies (loss
of function) support the effect of these variants in the patho-
genesis of PAH.
In the ACVRL1 gene 16 missenses and one nonsense
variants were reported (Table 1). Thirteen variants
(81.25%) were predicted as pathogenic (Table 2). None of
these variants were identified in ESP or ExAC databases.
One in vitro functional study used NIH 3T3 fibroblasts and
COS‐7 cells analyzing the protein expression of three
PAH‐associated variants (p.L381P, p.R484Q and
p.R484W) (Ricard et al., 2010). The study reported that
p.R484Q and p.R484W were inactive in the transactivation
step (Ricard et al., 2010). The mutated protein of p.L381P
did not respond to the bone morphogenetic protein 9
(BMP9) stimulation (loss of function) (Ricard et al., 2010).
These findings support the hypothesis of the role of
mutated proteins in ACVRL1 in pathogenesis of PAH,
despite the lack of data of familial cosegregation.
The two PAH‐associated variants in BMPR1B gene
were investigated in a functional study by using COS1
cells (Chida et al., 2012). They showed that amino acid
changes in p.F392L and p.S160N increased the activation
of proteins above wild‐type (gain of function) (Chida et al.,
2012). The p.S160N and p.F392L identified are unlikely to
be an important cause of development of PAH based on
results of the functional study. Furthermore, the p.S160N
and p.F392L were predicted VUS, which supports the
result of the functional study (Table 2; Chida et al., 2012).
To describe the function of all six variants in KCNK3,
Lijiang Ma et al. performed a functional analysis by using
COS‐7 cells (Ma et al., 2013). The mutated proteins
showed the loss of ion‐channel function (Ma et al., 2013).
Supporting these results, our in silico prediction analysis
predicted that all PAH‐associated variants in KCNK3
except p.V221L were pathogenic (Table 2).
Burg ED et al. analyzed the mutated protein of
p.E211D and p.G182R in KCNA5 gene (Burg, Platoshyn,
Tsigelny, Lozano‐Ruiz, & Rana, 2010). In an in vitro
study, they compared the function of mutated proteins with
wild type using human embryonic kidney cells (HEK‐293)
and COS‐1 (Burg et al., 2010). They found that mutated
proteins accelerated the inactivity of the voltage‐gated K+
(K(V)) channels, which have an important role in regulat-
ing PASMCs (Burg et al., 2010). These findings support
the role of p.E211D and p.G182R in KCNA5 gene as
uncommon cause of the etiology of PAH, although these
two variants predicted as VUS (Tables 2, 3 and 4).
Song et al. (2016) identified the p.Y311* as a heterozy-
gote mutation in EIF2AK4 gene in an heritable or idio-
pathic PAH patient. The p.Y311*/EIF2AK4 was not
present in the ESP and ExAC. A functional characterization
of p.Y311* by a protein‐expression study and cosegrega-
tion analysis in a pedigree will support the role of
p.Y311*/EIF2AK4 in pathogenesis of PAH.
5 | CONCLUSION
To our knowledge, this is the first evaluation of previously
reported rare PAH‐associated genes and variants. In the
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literature, we found 14 genes and 180 missense/nonsense
variants. BMPR2 were identified to be the most important
and common reported cause of PAH.
By using prediction analysis and the allele frequency of
PAH‐associated variants in TOPBP1 and ENG genes in the
background population, suggests that these variants are
unlikely to be the monogenic cause of the PAH pathogene-
sis. Further functional studies are required to clarify the
function of mutated proteins.
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